九安醫療(002432.SZ):iHealth新型冠狀病毒、甲型流感病毒及乙型流感病毒三聯檢測試劑盒已經通過線上和線下渠道進行銷售
格隆匯7月24日丨九安醫療(002432.SZ)在投資者互動平台表示,目前公司的iHealth新型冠狀病毒、甲型流感病毒及乙型流感病毒三聯檢測試劑盒已經通過線上和線下渠道進行銷售,其中線上銷售渠道包括美國子公司官網、亞馬遜平台等,以TO C端銷售為主,線下渠道包括TO B和TO C端銷售。該產品上市時間較短,銷售情況尚無法預計,公司具體銷售收入情況敬請關注公司定期報吿,公司將密切關注市場需求,進一步拓展市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.